Diamond Blackfan Anemia Diamond-Blackfan Anemia is a rare, inherited bone marrow failure disorder that affects the body’s ability to produce a sufficient amount of healthy red blood cells. In contrast to other blood disorders that affect multiple types of blood cells, DBA selectively impairs the production of red blood cells, resulting in chronic anemia that typically begins during the first year of life.[1]
What is Diamond-Blackfan Anemia?: Diamond Blackfan Anemia
Diamond-Blackfan Anemia is a rare genetic disease that interferes with the production of red blood cells by the bone marrow. In other words, bone marrow is a factory that manufactures different types of blood cells. In DBA, the specific “assembly line” that creates red blood cells is broken or severely impaired.
Red blood cells are crucial for carrying oxygen from your lungs to every part of your body. As a result, when the bone marrow cannot produce enough of these vital cells, the result is chronic anemia, a condition where your blood cannot carry adequate oxygen to meet your body’s needs.[2]
Diamond-Blackfan Anemia differs from other bone marrow failure syndromes, which affect various types of blood cells; the disease selectively affects the production of red blood cells. On average, white blood cells and platelets are at normal levels, and this helps the doctor differentiate DBA from other related conditions.
The condition was named after physicians Louis Diamond and Kenneth Blackfan, who described the condition first in the 1930s. DBA is considered a very rare disease, occurring in approximately 1 in 100,000 to 200,000 births.[3] The diagnosis is made in most cases in infancy, and approximately 90 percent of patients have symptoms before their first birthday.
Causes and Genetics
To understand the causes of diamond-blackfan anemia, it is necessary to start with the genetic background of the disease. DBA is mainly a genetic disease that is brought about by mutations in genes that encode ribosomal proteins (protein building blocks) within the cell machinery, required to develop red blood cells.
The most commonly affected genes are RPS19, RPS24, RPS17, RPL5, and RPS26; additionally, several other genes in the ribosomal protein gene family are also involved. These mutations interfere with the function of ribosomes, which are “the protein factories” in the cells. When these factories are not working well, they cannot maintain the complex process of red blood cell maturation, resulting in the typical anemia that occurs in DBA.[4]
About 45-50 percent of all cases can be traced to known genetic mutations. However, in the remaining cases, the specific genetic cause remains unknown, though researchers continue to identify new gene mutations associated with the condition.
DBA is usually inherited in an autosomal dominant manner, i.e., only one mutated gene is required to be inherited from either parent to develop the condition. However, about 10-25% of cases occur sporadically, with no family history of the disorder. This happens when the genetic mutation occurs for the first time in the affected individual.[5]
Parents of children with DBA often wonder about the risk to future children. If one parent has DBA, there is a 50% chance that each child will inherit the condition. Genetic counseling can provide families with detailed information about their specific situation and help them make informed decisions about family planning.
Signs & Symptoms of Diamond-Blackfan Anemia
The symptoms typically manifest during the first year of life, with the majority of infants exhibiting them by the age of six months. The primary symptoms result from the body’s inability to produce sufficient red blood cells, leading to chronic anemia.[6]
Primary Symptoms of Anemia:
- Pale skin, lips, and nail beds: This is the first external manifestation in most cases.
- Excessive fatigue and sleepiness: Infants may seem unusually tired or lethargic
- Rapid heartbeat (tachycardia): The heart works harder to pump oxygen-poor blood
- Heart murmur: May develop as the heart compensates for low oxygen levels
- Shortness of breath: Especially noticeable during feeding or physical activity
- Poor feeding and slow weight gain: Common in affected infants
- Irritability: Due to the body’s struggle to get enough oxygen
In addition, about half of all people with Diamond-Blackfan Anemia also have physical abnormalities.
Physical Abnormalities: About half of all people with Diamond Blackfan Anemia have physical abnormalities, although these may be very different in each case. These may include:[7]
- Craniofacial features: Cleft palate, small nose, wide-set eyes
- Thumb abnormalities: Absent, underdeveloped, or extra thumbs
- Short stature: Growth delays are common
- Heart defects: Various congenital heart abnormalities
- Kidney abnormalities: Structural or functional kidney problems
- Abnormalities of the genitals, especially in males
Nevertheless, it is worth mentioning that all these abnormalities vary widely with DBA. Some of the patients do not have a physical abnormality at all, while others possess several features.
Early anemia is mild, and this is why DBA is not always diagnosed at the start. Parents should notice their instincts in case they suspect that their child appears to be abnormally pale, fatigued, or simply not developing as he or she should, and contact their pediatrician to have the child properly examined.
How is DBA Diagnosed?
Diamond-Blackfan anemia requires some specific tests and assessments for diagnosis. It is vital to diagnose the condition early and correctly to proceed with the therapeutic intervention and to monitor the possible complications.[8]
Blood Tests:
The diagnostic process usually starts with an extensive blood analysis, which shows:
- Severe anemia: Low red blood cell count and hemoglobin levels
- Elevated adenosine deaminase (ADA) levels: Found in about 85% of DBA patients
- Normal white blood cell counts: Distinguishing DBA from other bone marrow disorders
- Normal or slightly elevated platelet counts
- Macrocytic anemia: Red blood cells may be larger than normal
- High levels of fetal hemoglobin: May persist longer than typical
Bone Marrow Examination:
A bone marrow biopsy is still the gold standard in the diagnosis of DBA. It is done under sedation, and a small sample of bone marrow is taken and viewed under a microscope. In DBA, the bone marrow shows:
- Severely reduced red blood cell precursors
- Normal numbers of white blood cells and platelet precursors
- No evidence of other bone marrow disorders
Genetic Testing:
Moreover, genetic testing can identify mutations in known DBA-associated genes, confirming the diagnosis in about 45-50% of cases. However, when no mutation is found, this does not rule out DBA.[9]
Additional Evaluations:
Since DBA may impair several organ systems, recently diagnosed patients usually have the following:
- An echocardiogram to test for heart abnormalities
- Kidney function tests and imaging
- Growth and developmental assessments
- Hearing and vision evaluations
The process of diagnosis needs an expert hematologist working on bone marrow failure syndromes. When possible, parents must consult a specialized centre because diagnosis and treatment of DBA cannot be conducted by just anyone.
Diamond-Blackfan Anemia vs. Fanconi Anemia
One of the most important distinctions in diagnosing bone marrow failure syndromes is understanding Diamond-Blackfan anemia vs Fanconi anemia. Although the two conditions affect blood cell production, they differ in various aspects that influence the diagnosis, treatment, and prognosis.
| Feature | Diamond Blackfan Anemia (DBA) | Fanconi Anemia (FA) |
|---|---|---|
| Primary Defect | Ribosomal protein genes affecting red blood cell production | DNA repair genes cause genome instability |
| Blood Cells Affected | Primarilyred blood cells | All blood cells(pancytopenia) |
| Age of Onset | Infancy (usually the first year) | Childhood to adolescence (typically later than DBA) |
| Key Blood Findings | Severe anemia with normal white cells and platelets | Progressive decline in all blood cell types |
| Physical Abnormalities | Present in ~50% of patients (craniofacial, thumb, heart) | Present in ~75% of patients (cafe-au-lait spots, thumb abnormalities) |
| Cancer Risk | Slightly increased risk of colon cancer | Significantly increased risk of multiple cancers |
| Chromosomal Breakage Test | Normal | Abnormal (key diagnostic test for FA) |
| Treatment Response | Often responds to corticosteroids | Does not respond to steroids |
On the other hand, of particular relevance in distinguishing these conditions is the chromosomal breakage test. Exposure of Fanconi anemia cells to some chemicals leads to characteristic chromosome breaks, whereas this abnormality is not evident in DBA cells.
Treatment Options for Diamond-Blackfan Anemia
Modern diamond blackfan anemia treatment has significantly improved the outlook for patients with this condition. Although treatment is not possible yet, with the exception of stem cell transplantation, symptoms can be controlled with effective treatment, and people can lead productive lives.
Corticosteroids – First-Line Treatment:
Prednisone (and other corticosteroids) is the main medication used in Diamond-Blackfan Anemia treatment. Approximately 80% of patients respond to steroid therapy, at least initially. These medications work by:[10]
- Stimulating red blood cell production in the bone marrow
- Reducing inflammation that may interfere with blood cell development
- Improving the survival of existing red blood cells
Steroid treatment aims to achieve the minimum effective dose required to keep the hemoglobin normal with minimal side effects. Higher doses are usually used at the start of the treatment, and these doses are slowly decreased to the minimum effective dose.
Potential side effects of long-term steroid use include:
- Growth suppression in children
- Increased risk of infections
- Bone thinning (osteoporosis)
- High blood pressure
- Mood changes
- Increased appetite and weight gain
The patient, monitored regularly by medical experts, helps to establish the optimal balance between the benefits of medication and the potential side effects.
Blood Transfusions:
For patients who don’t respond to steroids or cannot tolerate them, regular blood transfusions become necessary. Transfusion gives immediate relief to anemia symptoms by supplying healthy red blood cells. Most transfusion-dependent patients require transfusions every 3-4 weeks.[11]
Benefits of transfusion therapy:
- Immediate improvement in anemia symptoms
- Better quality of life and energy levels
- Normal growth and development
- Reduced stress on the heart and other organs
Iron Chelation Therapy:
Iron chelation therapy is an important part of transfusion-dependent treatment. Repeated blood transfusions result in the accumulation of iron in the organs, especially the heart and liver, which becomes very dangerous when untreated.
Iron chelation medications include:
- Deferasirox (Exjade): Oral medication taken daily
- Deferoxamine (Desferal): Given by injection or continuous infusion
- Deferiprone (Ferriprox): Oral medication, less commonly used
As the iron level is monitored regularly with blood tests and MRI, chelation therapy is guided, and iron-associated complications are prevented.
Stem Cell Transplantation:
Hematopoietic stem cell transplantation (bone marrow transplant) remains the only potential cure for Diamond-Blackfan Anemia. This treatment involves replacing the patient’s faulty bone marrow with healthy stem cells from a compatible donor.
Considerations for transplantation:
- Best outcomes occur with matched sibling donors
- The procedure carries significant risks, including graft-versus-host disease
- Generally reserved for severe cases or when other treatments fail
- Success rates are improving with advances in transplant techniques
The decision to pursue transplantation requires careful consideration of risks and benefits, taking into account the patient’s current health, available donors, and response to other treatments.
Outlook & Life Expectancy
Naturally, families diagnosed with Diamond-Blackfan Anemia are worried about the life expectancy and long-term prognosis. Though DBA is a life-long disorder, the prognosis has been getting better due to the development in modern medical care and treatment measures.[12]
Factors Affecting Prognosis:
Depending on a variety of factors, the long-term prospects of persons with DBA are good:
- Response to first-line steroid therapy
- Treatment-related complications
- Existence of physical abnormalities
- Specialized medical care is available
- Treatment and monitoring compliance
Treatment Response and Outcomes:
Corticosteroid therapy initially responds in about 80 percent of patients and tends to provide better long-term results. Those patients who can control their red blood cell count on low-dose steroids enjoy a very high-quality life with very few side effects related to the treatment.
In patients who require transfusion, regular transfusion and iron chelation therapy are important in preventing complications. Overall, with proper management, most patients live well into adulthood.[13]
Long-Term Monitoring:
All patients with Diamond-Blackfan Anemia require lifelong follow-up. Regular observation involves:
- Assess iron level and blood counts regularly
- Evaluation of heart function (echocardiograms)
- Liver function monitoring
- Bone density screening
- Surveillance of cancer (slightly increased colon cancer risk)
- Child development and growth assessments.
Quality of Life Considerations:
With DBA, many people enjoy full and productive lives in their education, careers, and families. The most important aspects of a good quality of life are:
- Regular medical care and adhere strictly to your treatment
- Strong support systems
- Do regular physical activity as tolerated
- Counseling for mental health when needed
- Connection with a patient support organization
Recent Advances:
Some new treatments currently being investigated are gene therapy and new drugs that can stimulate the production of red blood cells by mechanisms other than steroids.
Conclusion
Diamond-Blackfan Anemia is a rare but manageable condition that requires lifelong medical care, early diagnosis, and consistent monitoring. While it presents significant challenges, such as chronic anemia, potential physical abnormalities, and treatment-related complications, advances in modern therapies have greatly improved the outlook for patients. Corticosteroids, blood transfusions, iron chelation, and in some cases, stem cell transplantation allow many individuals with DBA to live healthy and productive lives. Ongoing research into gene therapy and novel treatments offers hope for even more effective solutions in the future. With the right medical team, strong family and community support, and active engagement in treatment, patients and families can face this condition with resilience and optimism. Ultimately, living with DBA is not just about managing a disease; it’s about ensuring quality of life, growth, and the opportunity to thrive.
References
[1] Diamond, L. K., & Blackfan, K. D. (1938). Congenital hypoplastic anemia.American Journal of Diseases of Children, 56(3), 464–467.
[2] Vlachos, A., Muir, E., & Lipton, J. M. (2008). Diamond Blackfan Anemia: A model for the study of the pathogenesis and treatment of bone marrow failure.Seminars in Hematology, 45(2), 95–104.
[3] Lipton, J. M., & Ellis, S. R. (2009). Diamond Blackfan Anemia: Diagnosis, Treatment and Molecular Pathogenesis.Hematology/Oncology Clinics of North America, 23(2), 261-282.
[4] Narla, A., & Ebert, B. L. (2010). Ribosomopathies: Human disorders of ribosome dysfunction.Blood, 115(16), 3196–3205.
[5] Da Costa, L., Narla, A., & Mohandas, N. (2018). Diamond-Blackfan anemia, ribosome and erythropoiesis.Current Opinion in Pediatrics, 30(1), 1–7.
[6] Vlachos, A., & Muir, E. (2010). How I treat Diamond-Blackfan anemia.Blood, 116(19), 3715–3723.
[7] Lipton, J. M., & Ellis, S. R. (2009). Diamond-Blackfan anemia: Diagnosis, treatment, and molecular pathogenesis.Hematology/Oncology Clinics of North America, 23(2), 261–282.
[8] Ball, S. E. (2011). Diamond Blackfan anemia.Hematology/Oncology Clinics of North America, 25(2), 247–259.
[9] Farrar, J. E., & Dahl, N. (2011). Untangling the phenotypic heterogeneity of Diamond Blackfan anemia.Seminars in Hematology, 48(2), 124–135.
[10] Vlachos, A., Rosenberg, P. S., Atsidaftos, E., Alter, B. P., & Lipton, J. M. (2012). Incidence of neoplasia in Diamond Blackfan anemia: A report from the Diamond Blackfan Anemia Registry.Blood, 119(16), 3815–3819.
[11] Ellis, S. R., & Gleizes, P. E. (2011). Diamond Blackfan anemia: Ribosomal proteins going rogue.Seminars in Hematology, 48(2), 89–96.
[12] Aspesi, A., & Ellis, S. R. (2019). Rare ribosomopathies reveal the importance of ribosomes in human health.Cell, 179(2), 225–240.
[13] Ulirsch, J. C., Verboon, J. M., Kazerounian, S., Guo, M. H., Yuan, D., Ludwig, L. S., & Sankaran, V. G. (2018). The genetic landscape of Diamond-Blackfan anemia.American Journal of Human Genetics, 103(6), 930–947.